L. E. Stopfer

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

This study shows MEK inhibition increases MHC-I antigen presentation in melanoma, enhancing immunotherapy efficacy through targeted epitopes.

Deciphering the tumor-specific immunopeptidome in vivo with genetically engineered mouse models

This paper uses genetically engineered mouse models to isolate and profile tumor-specific MHC-I peptides in vivo, revealing post-translational shaping of the immunopeptidome and novel tumor-associated antigens in lung adenocarcinoma.

Quantitative consequences of protein carriers in immunopeptidomics and tyrosine phosphorylation MS2 analyses

This study evaluates the impact of protein carriers on quantitative accuracy in immunopeptidomics and tyrosine phosphoproteomics, showing increased identifications but reduced accuracy and missing values in phosphoproteomics.

High-density, targeted monitoring of tyrosine phosphorylation reveals activated signaling networks in human tumors

This paper introduces SureQuant pTyr, a targeted mass spectrometry method for sensitive and reproducible profiling of tyrosine phosphorylation in human colorectal tumors, revealing dysregulated signaling networks.

Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition

This study uses a novel immunopeptidomics approach to quantify MHC I repertoire changes induced by CDK4/6 inhibition and interferon gamma in melanoma.